Research has shown that the expressions of NOD1, NOD2, NLRP3, caspase-1, and the release of IL-1β, IL-18, and TNF-α were upregulated in NAFLD intestine and reduced after treatment of BBR. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.